Exercise or conversion by Virani Shafique of 5000 shares of Recursion Pharmaceuticals subject to Rule 16b-3

RXRX Stock  USD 6.03  0.06  0.99%   
Slightly above 66% of Recursion Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Recursion Pharmaceuticals suggests that many traders are alarmed. Recursion Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Recursion Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Recursion Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Read at macroaxis.com
Recursion insider trading alert for exercise of stock option right to buy by Virani Shafique, Chief Business Officer, on 21st of April 2023. This event was filed by Recursion Pharmaceuticals with SEC on 2022-12-19. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Recursion Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Recursion Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Recursion Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Recursion Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Recursion Pharmaceuticals Historical Investor Sentiment

Investor biases related to Recursion Pharmaceuticals' public news can be used to forecast risks associated with an investment in Recursion. The trend in average sentiment can be used to explain how an investor holding Recursion can time the market purely based on public headlines and social activities around Recursion Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Recursion Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Recursion Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Recursion Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Recursion Pharmaceuticals.

Recursion Pharmaceuticals Fundamental Analysis

We analyze Recursion Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Recursion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Recursion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earnings To Growth

Price To Earnings To Growth Comparative Analysis

Recursion Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

Recursion Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Recursion Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Recursion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Recursion Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Recursion Pharmaceuticals Related Equities

OCEAOcean Biomedical   11.86   
0%
94.0%
INZYInozyme Pharma   6.41   
0%
51.0%
ABOSAcumen Pharmaceuticals   2.78   
0%
22.0%
DAWNDay One   2.65   
0%
21.0%
ABSIAbsci Corp   2.40   
0%
19.0%
AFMDAffimed NV   0.85   
0%
6.0%
ENVBEnveric Biosciences   1.52   
12.0%
0%
CNSPCns Pharmaceuticals   1.82   
14.0%
0%
IMMXImmix Biopharma   2.25   
18.0%
0%
RLAYRelay Therapeutics   2.35   
18.0%
0%
SANASana Biotechnology   2.37   
18.0%
0%
XFORX4 Pharmaceuticals   4.69   
37.0%
0%
HEPAHepion Pharmaceuticals   12.50   
100.0%
0%

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.